The momentum, though, appeared to be cooling.
On the morning of February 7, India's equity markets prepared to open in near-stillness — a pause after the previous session's recovery, when Sensex and Nifty both climbed back into the green. Yet beneath that surface quiet, the day carried real weight: a fintech founder sat across from a finance minister, a cancer drug found its way toward American patients, and the consumer goods sector readied itself for a reckoning with its own numbers. Markets, like seasons, rarely rest for long.
- After a solid rebound on February 6 — Sensex up 0.63%, Nifty crossing 21,900 — overnight signals pointed to a near-flat open, suggesting the rally's energy was already fading.
- Paytm remained a live wire: founder Vijay Shekhar Sharma's meeting with Finance Minister Nirmala Sitharaman kept regulatory uncertainty swirling around the embattled fintech firm.
- Biocon received tentative FDA approval for its Dasatinib cancer tablets, cracking open a door to the American market for a drug targeting a rare but serious blood cancer.
- Zurich Insurance won CCI clearance to acquire a 70% stake in Kotak Mahindra General Insurance, marking a significant foreign reshaping of India's insurance landscape.
- Britannia's Q3 profit fell sharply on paper — down 40% — but the drop reflected the absence of last year's exceptional gains rather than a true operational collapse.
- Nestle India and Tata Consumer Products were set to report results, with analysts expecting double-digit profit growth driven by volume, pricing power, and operating leverage.
India's stock market entered February 7 in a mood of cautious stillness. GIFT Nifty signals pointed to an opening gain of just 8 points — a whisper of momentum following Tuesday's more convincing recovery, when the Sensex added 454 points and the Nifty crossed 21,900 for the first time in days.
The real action was happening off the trading floor. Paytm founder Vijay Shekhar Sharma had met with Finance Minister Nirmala Sitharaman — a meeting whose contents stayed private but whose very occurrence reminded investors that the fintech company remained squarely in the government's field of vision. Meanwhile, Biocon secured tentative FDA approval for its Dasatinib tablets, a leukemia treatment in six dosage strengths, clearing a meaningful path into the U.S. pharmaceutical market. And Zurich Insurance received Competition Commission approval to take a 70% stake in Kotak Mahindra General Insurance, with a controlling 51% share acquired through fresh capital and secondary purchases.
On earnings, the picture was mixed but leaning hopeful. Britannia's Q3 profit appeared to crater — down 40% year-on-year — but the comparison was distorted by exceptional gains in the prior period that simply wouldn't recur. Berger Paints told a more straightforwardly positive story: profit up nearly 50%, revenue growing 7%, with lower raw material costs doing much of the heavy lifting. The day's most anticipated results belonged to Nestle India and Tata Consumer Products, both expected to post double-digit profit growth on the back of volume gains, pricing discipline, and the quiet compounding of operational scale.
The Indian stock market was bracing for a quiet Wednesday morning. Overnight signals from GIFT Nifty pointed to a muted opening, with the broader index expected to edge up just 8 points when the bell rang on February 7. This came after a day of recovery: on February 6, both the Sensex and Nifty had shaken off earlier losses and closed in the green. The Sensex had climbed 454.67 points—a gain of 0.63 percent—to settle at 72,186.09. The Nifty had risen 157.70 points, or 0.72 percent, crossing the 21,900 threshold to finish at 21,929.40. The momentum, though, appeared to be cooling.
But beneath the surface calm, several stocks were poised to move. Paytm's founder Vijay Shekhar Sharma had met with Finance Minister Nirmala Sitharaman, a conversation that would likely weigh on investor sentiment around the fintech company. The specifics of what was discussed remained opaque, but the meeting itself signaled that regulatory and government attention on Paytm remained active and worth watching.
Biocon, the biopharmaceutical manufacturer, had cleared a significant hurdle. The U.S. Food and Drug Administration had granted tentative approval for its Dasatinib tablets—a cancer treatment available in six different strengths ranging from 20 milligrams to 140 milligrams. The drug targets Philadelphia chromosome-positive chronic myeloid leukemia in adult patients, a rare but serious blood cancer. For Biocon, the approval opened a path into the American market for a drug that could generate meaningful revenue.
At Kotak Mahindra Bank, a major insurance deal had won regulatory blessing. The Competition Commission of India had approved Zurich Insurance Company's plan to acquire a 70 percent stake in Kotak Mahindra General Insurance Company. Zurich would take a 51 percent controlling stake through a combination of new capital and share purchases. The transaction represented a significant reshuffling of ownership in one of India's insurance businesses.
On the earnings front, the day promised a parade of results from India's consumer goods giants. Britannia Industries had already reported its third-quarter numbers: consolidated profit of Rs 555.66 crore, down 40.4 percent from the year before. The decline stung, but the company had faced an unusually high comparison—the prior year's quarter had included exceptional gains of Rs 375.6 crore that wouldn't repeat. Nestle India and Tata Consumer Products were both scheduled to announce results on February 7, and analysts expected both to deliver double-digit profit growth. Nestle's strength was expected to come from higher volumes and pricing power, combined with the efficiency gains that come from running a larger operation. Tata Consumer was similarly positioned, with growth driven by volume expansion in its domestic business, a stable international operation, and the same operating leverage benefits.
Berger Paints had already shown what strong execution could look like. The paint maker reported consolidated profit of Rs 300.2 crore for the October-to-December quarter, a jump of 49.2 percent year-over-year. Revenue from operations had grown 7 percent to Rs 2,882 crore, driven by solid operational performance and the tailwind of lower raw material costs. The company's results suggested that at least some corners of the consumer sector were firing on all cylinders, even as others struggled with margin pressure and demand softness.
Notable Quotes
Paytm founder Vijay Shekhar Sharma met with Finance Minister Nirmala Sitharaman, with discussion likely centered on current circumstances concerning Paytm— News18 reporting
Nestle India and Tata Consumer Products expected to announce double-digit profit growth for Q3, driven by volume expansion and operating leverage— Market analysts cited in reporting
The Hearth Conversation Another angle on the story
Why does a meeting between Paytm's founder and the Finance Minister matter enough to move a stock?
Because Paytm has been under regulatory scrutiny for months. The RBI had concerns about its operations. When the founder sits down with the Finance Minister, it signals either progress on resolving those concerns or new pressure coming. Investors need to know which.
And the Biocon approval—is that a big deal?
It's meaningful but not transformative. Dasatinib is a cancer drug, so the addressable market is real. But it's also a generic version of an existing drug, so Biocon enters a competitive space. Still, FDA approval is a gate you have to pass to sell in America, and they passed it.
Why are so many FMCG companies reporting on the same day?
That's just the calendar. Q3 ends December 31, so most companies report in early February. It's not coordinated—it's just how the fiscal year falls.
The Britannia numbers look bad. Down 40 percent?
They look worse than they are. Last year's quarter had a one-time gain of Rs 375 crore that inflated the number. Strip that out and the underlying business didn't collapse. But investors see the headline and react.
What does a flat market opening actually mean for trading?
It means the big institutional players aren't rushing in or out. It's a day where individual stock moves matter more than the overall direction. That's when news like the Zurich-Kotak deal or Biocon's approval can actually move prices.